Gapping up
In reaction to earnings/guidance:
- TWLO +20%, DDOG +14.1%, MQ +12.9% (expects to outperform prior Q4 revenue guidance; also names new CFO), CYBR +12.2%, MAT +10.9%, DIS +7.3%, BLBD +6.8%, STC +6.2%, INTA +5.7%, UBER +5.4%, SONO +5.4%, BAM +5.4%, ORLY +5%, ACGL +4.4%, LCII +4.4%, LH +3.7%, RAMP +3.5%, TPR +3.5%, CPA +3.3%, TWTR +3.3%, ASX +2.9%, DIOD +2.8%, AEIS +2.7%, PBF +2.7%, LIN +2.6%, AZN +2.5%, CHX +2.2%, ASGN +2%, TU +2%, MLM +1.8%, EFX +1.7%, WEX +1.7%, AFG +1.6%, MGM +1.6%, GFL +1.6%, WSO +1.5%, KIM +1.4%, INMD +1.4%, GPI +1.2%, TSM +1.1%, KO +1.1%, MFC +1%
Other news:
- IRNT +21.9% (signs contract with a Gulf Cooperation Council country)
- LH +8.3% (announces long-term laboratory relationship with Ascension)
- PNNT +4.3% (increases dividend and authorizes $25 mln share repurchase program)
- RRC +2.4% (announces Q4 production pricing cap-ex)
- OAS +2.3% (outlines return of capital plan provides preliminary 4Q21 results)
- AFMD +2.1% (announces the publication of pre-clinical data)
- HGEN +1.9% (Launches Managed Access Program for Lenzilumab)
- SGFY +1.7% (signed an agreement to acquire Caravan Health for an initial purchase price of ~$250 mln in a combination of cash and Signify Health common stock)
- SST +1.5% (stock offering)
- TEAM +1.3% (exploring redomiciling of its parent holding co from UK to the US)
- PHAT +1.2% (announces top-line results from Phase 2 PHALCON-NERD trial of vonoprazan)
- CRM +1.1% (tells employees it plans to release an NFT Cloud according to CNBC)
- RDN +1.1% (increases dividend and authorizes $400 mln share repurchase program)
- PBR +1.1% (reports its reached production targets for FY21)
- GSK +0.9% (receives approval for Benlysta from China's National Medical Products Administration)
Analyst comments:
- AMBA +4.3% (upgraded to Outperform from Neutral at Robert W. Baird)
- CCOI +3% (upgraded to Overweight from Neutral at JP Morgan)
- THC +1.6% (upgraded to Buy from Neutral at UBS)
- STNG +1.3% (upgraded to Neutral from Underperform at BofA Securities)